Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of LMPTP, compositions, and methods of using these compounds and compositions.

The present inventors have arrived at the present application by confirming that a novel quinazolinone derivative exhibits therapeutic efficacy for metabolic disorders. The quinazolinone derivative according to the present application has a similar structure to that of idelalisib, but exhibits very different properties and a different mechanism of action from idelalisib. In addition, this derivative molecule was shown to have excellent efficacy against metabolic disorders, in particular lipid metabolic disorders, through different mechanism of action. The derivative molecule also showed excellent efficacy against non-alcoholic steatohepatitis (NASH). No non-alcoholic steatohepatitis treatment drugs have been approved at the time of filing.

The present inventors have arrived at the present application by confirming that a novel quinazolinone derivative exhibits therapeutic efficacy for metabolic disorders. The quinazolinone derivative according to the present application has a similar structure to that of idelalisib, but exhibits very different properties and a different mechanism of action from idelalisib. In addition, this derivative molecule was shown to have excellent efficacy against metabolic disorders, in particular lipid metabolic disorders, through different mechanism of action. The derivative molecule also showed excellent efficacy against non-alcoholic steatohepatitis (NASH). No non-alcoholic steatohepatitis treatment drugs have been approved at the time of filing.

The present disclosure provides pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

The present disclosure provides pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives represented by formula (IA) and (IB), processes for preparing the alcohol derivatives and their use in preparing pharmaceuticals.

The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives represented by formula (IA) and (IB), processes for preparing the alcohol derivatives and their use in preparing pharmaceuticals.

The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, and other complications associated with these diseases and disorders.

The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, and other complications associated with these diseases and disorders.

The disclosure provides for novel antimicrobial agents, methods of making, and methods of use thereof.